Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 10/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | POLQ | O75417 | 4/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7663596 | 0.91 | CTSL (0.47) | CTSLEPHX2CTSSCTSBCTSK | |
| SCHEMBL6744437 | 0.90 | CTSL (0.46) | CTSLEPHX2TACR1CTSSCTSB | |
| SCHEMBL6740918 | 0.90 | EPHX2 (0.47) | CTSLEPHX2CTSSCTSBCTSK | |
| SCHEMBL7662418 | 0.89 | CTSL (0.46) | CTSLTACR1CTSSCTSBMRGPRX4 | |
| SCHEMBL6741513 | 0.88 | CTSL (0.46) | CTSLTACR1CTSSCTSBMRGPRX4 | |
| SCHEMBL6744103 | 0.86 | CTSL (0.53) | CTSLCTSSCTSBMRGPRX4CTSK | |
| SCHEMBL7661637 | 0.86 | CTSL (0.49) | CTSLTACR1CTSSCTSBMRGPRX4 | |
| SCHEMBL6062636 | 0.86 | CTSL (0.46) | CTSLTACR1CTSSCTSBMRGPRX4 | |
| SCHEMBL7666657 | 0.85 | EPHX2 (0.42) | CTSLEPHX2CTSSCTSBCTSK | |
| SCHEMBL6841822 | 0.83 | CTSL (0.42) | CTSLEPHX2CTSSCTSBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | CTSL 10/4885EPHX2 2297/4885POLQ 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.